Private Securities Litigation Reform Act

Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 3, 2022
G&A, Jude the Apostle, DMD, FDA, Investor, Adult, FSHD, University, Research, U.S. Securities and Exchange Commission, R, SEC, CA, FORCE, Food, MAD, GLOBE, Congress, University of Milan, Science, Dystrophin, Nucleic Acids Research, Duchenne muscular dystrophy, Security (finance), Patient, Muscle, Pharmacokinetics, DM1, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Degenerative disease, Private Securities Litigation Reform Act, Terminology, COVID-19, Review, National Institutes of Health Clinical Center, Hospital, Fast Track, Clinic, Nucleic acid, Therapy, Tissue, Safety, Conference, Facioscapulohumeral muscular dystrophy, Nasdaq, Form 10-Q, Credit, Credit Suisse, DYN, Center, Pharmaceutical industry, Medical imaging, Air cargo, Lease, Neurology, Dyne, Facebook

WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2022 and business highlights.

Key Points: 
  • WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2022 and business highlights.
  • In the third quarter of 2022 we marked incredibly important milestones for Dyne with the initiation of patient clinical trials for our two lead product candidates, DYNE-101 and DYNE-251.
  • In October 2022, Dyne announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for DYNE-251.
  • Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.

Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, November 3, 2022
Company, Private Securities Litigation Reform Act, Exercise, Sale, Association, GLOBE, Probability, Neuro, FDA, Investor, Population, Safety, ACTION, Conference, Biomedical Advanced Research and Development Authority, HIV disease progression rates, Conference call, NDA, Research, U.S. Securities and Exchange Commission, Data, New Drug Application, Forward-looking statement, ID, Acceleration, Glioma, NASDAQ, Development, Human, Agency, Society, Emergent, Patient, BARDA, Pharmaceutical industry, Video game, Security (finance), ONC201

DURHAM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an operational update.

Key Points: 
  • In the meantime, we remain disciplined with spend across the organization as we complete the transition of TEMBEXAto Emergent.
  • Chimerix recorded a net loss of $18.6 million, or $0.21 per basic and diluted share, for the third quarter of 2021.
  • General and administrative expenses increased to $5.3 million for the third quarter of 2022, compared to $4.9 million for the same period in 2021.
  • Chimerix will host a conference call and live audio webcast to discuss third quarter 2022 financial results and provide a business update today at 8:30 a.m.

Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023

Retrieved on: 
Thursday, November 3, 2022
G&A, HD, Outline, Private Securities Litigation Reform Act, Risk, Investment, Glaucoma, Guillain, GLOBE, Complement component 1q, Brain, Securities Exchange Act of 1934, Terminology, C3, Nasdaq, COVID-19, ARCHER, Review, Securities Act of 1933, HSG, Annual general meeting, Research, CSF, GBS, Forward-looking statement, GA, Drug Quality and Security Act, Ophthalmology, Neurodegeneration, Immune system, R, Disease, Intravenous therapy, Geographic atrophy, Eye, SEC, Autoimmunity, Program, Vaccine, Pharmaceutical industry, Patient, Pharmacokinetics, Safety, Retina

BRISBANE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today reported third quarter 2022 financial results. Additionally, Annexon announced plans to provide updates and outline anticipated milestones across its business and portfolio of complement-targeted therapies in January 2023.

Key Points: 
  • Additionally, Annexon announced plans to provide updates and outline anticipated milestones across its business and portfolio of complement-targeted therapies in January 2023.
  • We are also excited about ANX007, which has demonstrated target engagement and tissue penetration preclinically and in patients.
  • With the most comprehensive classical complement pipeline in development, were rigorously pursuing multiple paths to drive value across our portfolio for patients, employees and our supporters.
  • Research and development (R&D) expenses: R&D expenses were $27.9 million for the quarter ended September 30, 2022, compared to $27.6 million for the quarter ended September 30, 2021.

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Company, Protein, Cytopenia, Private Securities Litigation Reform Act, Degenerative disease, Research, Blood, Growth, Investment, Maintenance, Society, Tissue, Microdeletion syndrome, GLOBE, Hand, Intellectual property, Thrombocytopenia, COVID-19, Therapy, Ruxolitinib, Hypertrophy, U.S. Securities and Exchange Commission, Hypertensive emergency, KROS, ATM, Anemia, Security (finance), SEC, Achievement, Patient, Pharmaceutical industry

Keros continued to build upon the positive momentum of our pipeline programs in the third quarter of 2022.

Key Points: 
  • Keros continued to build upon the positive momentum of our pipeline programs in the third quarter of 2022.
  • Keros reported a net loss of $23.5 million in the third quarter of 2022 as compared to a net loss of $20.3 million in the third quarter of 2021.
  • Research and development expenses were $21.0 million for the third quarter of 2022 as compared to $14.8 million for the same period in 2021.
  • Keros cash and cash equivalents as of September30, 2022 was $239.4 million compared to $230.0 million as of December 31, 2021.

ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®

Retrieved on: 
Thursday, November 3, 2022
Glucose, Private Securities Litigation Reform Act, Diet, Type 2 diabetes, Alloxan, Weight loss, SAN, CA, Obesity, PG, Risk, Industry, GLOBE, Vagotomy, SBIR, Ramakanta Panda, FDA, Safety, Metabolic disorder, Patient, Nasdaq, Plasma, Oxidative stress, Marketing, Roy Taylor (scientist), Research, Vagus nerve, Type 2, Anatomy, Collection, Annual report, U.S. Securities and Exchange Commission, Insulin, Stomach, Pancreas, Diabetes, Forward-looking statement, Reshaping Cultural Policies, CV, Liver, Technology, Security (finance), NIH, Hypoglycemia, SD, Insulin resistance, Ligation, Person, Miniature pig, Pharmaceutical industry, Medical device, T2DM

Despite medication, surgery and diet, type 2 diabetes remains challenging to effectively treat, stated Jonathan Waataja, Director of Research at ReShape Lifesciences.

Key Points: 
  • Despite medication, surgery and diet, type 2 diabetes remains challenging to effectively treat, stated Jonathan Waataja, Director of Research at ReShape Lifesciences.
  • Previously, the area under the curve of oral glucose tolerance tests (OGTTs) was calculated to quantify glycemic control.
  • The opportunity to present such compelling data on our proprietary DBSN device at this industry conference is a testament to the market potential of the technology to treat type 2 diabetes, stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.
  • The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders.

Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022

Retrieved on: 
Thursday, November 3, 2022
Company, Neuroscience, Private Securities Litigation Reform Act, Migraine, Conditional sentence, Risk, AbbVie, GLOBE, COVID-19, Nasdaq, Annual report, Social media, U.S. Securities and Exchange Commission, Green Cross (South Korean company), Forward-looking statement, Vaccine, Health, Hypercholesterolemia, R, Technology, Security (finance), Amgen, Efficiency, Pharmaceutical industry, DALLAS

DALLAS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that it will host its first in-person and virtual Analyst and R&D Day in New York on Thursday, November 10, 2022 from 8:30 a.m. to 12:30 p.m. ET.

Key Points: 
  • Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe.
  • For more information about Vaxxinity, Inc., visit http://www.vaxxinity.com and follow us on social media @vaxxinity.
  • The use of certain words, including "potentially," and "will" and similar expressions, are intended to identify forward-looking statements.
  • These forward-looking statements involve substantial risks and uncertainties, and are based on the current expectations and assumptions of Vaxxinitys management.

Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Chronic lymphocytic leukemia, Private Securities Litigation Reform Act, Exercise, Research, Lymphatic system, Docetaxel, SAN, Food, Society, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Letter, CAR, FDA, MCRPC, BLA, IND, ASH, National, Castration, Therapy, Trial of the century, Nasdaq, ROR1, CD19, Review, CEO, U.S. Securities and Exchange Commission, Clinical trial, Forward-looking statement, MCL, Cancer, Risk, Drug development, NIH, U.S. FDA, Drug discovery, Patient, Prostate cancer, CLL, Venetoclax, Pharmaceutical industry

Our grant revenue is derived from two research and development grant awards from the National Institutes of Health (NIH).

Key Points: 
  • Our grant revenue is derived from two research and development grant awards from the National Institutes of Health (NIH).
  • Our total operating expenses for the third quarter ended September 30, 2022 were $11.7 million, including $2.0 million in non-cash stock-based compensation expense.
  • Research and development expenses for the quarter totaled $8.4 million, and general and administrative expenses for the quarter totaled $3.3 million.
  • Net loss for the third quarter was $11.1 million, or a loss of $0.21 per share, basic and diluted.

RAVE Restaurant Group, Inc. Reports First Quarter Results

Retrieved on: 
Thursday, November 3, 2022
Company, Private Securities Litigation Reform Act, Growth, Pie Five, Sale, Industry, GLOBE, Income, Solano, Jojo, Method, COVID-19, EBITDA, Tax, Family, Adjustment, Mission statement, Social media, NASDAQ, Milk, RAVE, Depreciation, Restaurant, Video game, Hospitality industry, Pizza Inn

DALLAS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- RAVE Restaurant Group, Inc. (NASDAQ: RAVE) today reported financial results for the first quarter of fiscal 2023 ended September 25, 2022.

Key Points: 
  • DALLAS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- RAVE Restaurant Group, Inc. (NASDAQ: RAVE) today reported financial results for the first quarter of fiscal 2023 ended September 25, 2022.
  • The Company used $1.4 million to repurchase shares of its common stock in the first quarter of fiscal 2023.
  • Cash and cash equivalents decreased $0.3 million during the first quarter of fiscal 2023 to $7.4 million at September 25, 2022.
  • Dallas-based RAVE Restaurant Group [NASDAQ: RAVE] has inspired restaurant innovation and countless customer smiles with its trailblazing pizza concepts.

Agrify Announces Successful Commercialization of Recently Launched PX10 Hydrocarbon Cannabis Extractor

Retrieved on: 
Thursday, November 3, 2022
ROI, Private Securities Litigation Reform Act, Research, Science, Electroputere VFU, GLOBE, Nasdaq, Ethanol, Annual report, U.S. Securities and Exchange Commission, Forward-looking statement, Alchemy, Technology, Security (finance), Cannabis, SEC, Communication, Solution, Drug, Fine chemical, Risk management

BILLERICA, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq:AGFY) (Agrify or the Company), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced that its recently launched PX10 hydrocarbon cannabis extractor will soon be installed at three customer facilities, including through a new engagement with Alchemist Ventures (Alchemist) in Maryland.

Key Points: 
  • BILLERICA, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq:AGFY) (Agrify or the Company), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced that its recently launched PX10 hydrocarbon cannabis extractor will soon be installed at three customer facilities, including through a new engagement with Alchemist Ventures (Alchemist) in Maryland.
  • The PX10 hydrocarbon cannabis extractor is the latest breakthrough from Agrify demonstrating the Companys continued emphasis on developing, commercializing, and deploying best-in-class solutions across both cultivation and extraction.
  • The PX10 was officially unveiled in August to provide customers the most advanced and scalable hydrocarbon extraction technology.
  • Agrify is a leading provider of innovative cultivation and extraction solutions for the cannabis industry, bringing data, science, and technology to the forefront of the market.

Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

Retrieved on: 
Thursday, November 3, 2022
Company, Journal, Private Securities Litigation Reform Act, American College, Primary biliary cholangitis, Board, The Journal of Clinical Pharmacology, Serica, GLOBE, American College of Clinical Pharmacology, Atopic dermatitis, Chronic kidney disease, FDA, Translational medicine, Medicine, Senior, Itch, CEP, Therapy, Nasdaq, Michigan State University, Form 10-Q, Alkermes, Pharmacology, U.S. Securities and Exchange Commission, David Berry (inventor), Wellesley College, Board of directors, Notalgia paresthetica, Security (finance), Michigan State University College of Human Medicine, Patient, Pharmaceutical industry

STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors.

Key Points: 
  • STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors.
  • Dr. von Moltke currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc.
    We are very pleased to welcome Lisa to our board of directors, said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics.
  • Its an exciting time to be joining the board of Cara Therapeutics, said Dr. von Moltke.
  • Dr. von Moltke has directed successful development programs, led clinical teams, and interacted with regulatory agencies across multiple therapeutic areas.